Enzon Pharmaceuticals (OTCMKTS:ENZN – Get Free Report) issued its earnings results on Monday. The biotechnology company reported ($0.84) earnings per share for the quarter, Zacks reports.
Enzon Pharmaceuticals Stock Performance
ENZN traded up $0.12 during trading on Monday, reaching $6.50. 159 shares of the stock were exchanged, compared to its average volume of 1,162. The stock has a market cap of $4.81 million, a P/E ratio of -0.93 and a beta of -0.03. Enzon Pharmaceuticals has a twelve month low of $1.50 and a twelve month high of $12.99. The stock’s 50 day moving average price is $6.08 and its two-hundred day moving average price is $5.59.
Enzon Pharmaceuticals Company Profile
Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.
The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.
Featured Stories
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
